Ph II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC
Authors
Arce-Lara, CArriola, E
Brunsvig, P
Carcereny, E
Domine, M
Dragnev, K
Felip, E
Campelo, R
Krebs, Matthew G
Paz-Ares, L
Aix, S
Spicer, J
Trigo, J
Segarra, V
Holt, R
Micklem, D
Brown, A
Chisamore, M
Lorens, J
Affiliation
Medicine, Medical College of Wisconsin, Milwaukee/WI/USIssue Date
2018
Metadata
Show full item recordCitation
Arce-Lara C, Arriola E, Brunsvig P, Carcereny E, Domine M, Dragnev K, et al. P2.04-27 Ph II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC. J Thorac Oncol. 2018;13(10):S741.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2018.08.1251Additional Links
https://dx.doi.org/10.1016/j.jtho.2018.08.1251Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2018.08.1251